Brief: Mustang Bio Provides Updates On Its Lentiviral Gene Therapies For The Treatment Of X-Linked Severe Combined Immunodeficiency

Mustang Bio

02/02/2021 12:35

Feb 2 (Reuters) - Mustang Bio Inc  MBIO.O :
    * MUSTANG BIO PROVIDES UPDATES ON ITS LENTIVIRAL GENE
THERAPIES
FOR THE TREATMENT OF X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
(“XSCID”)
    * MUSTANG BIO INC - FDA REMOVES CLINICAL HOLD FOR PIVOTAL
PHASE 2
MB-107 CLINICAL TRIAL
    * MUSTANG BIO INC - PLANS TO ENROLL FIRST PATIENT IN MB-107
PIVOTAL TRIAL IN Q2 OF 2021
    * MUSTANG BIO INC - CLINICAL OUTCOMES IN INVESTIGATOR-IND
XSCID
TRIALS CONTINUE TO SHOW COMPELLING EFFICACY
    * MUSTANG BIO - NO SERIOUS ADVERSE EVENTS RELATED TO
TREATMENT
WERE REPORTED IN MB-107 TRIAL
    * MUSTANG BIO INC - ENROLLMENT WILL CONTINUE AT ALL THREE
CLINICAL
SITES UNTIL CO INITIATES ITS MULTICENTER PIVOTAL PHASE 2 TRIAL
OF MB-107

Source text for Eikon:  ID:nGNX5J04jX 
Further company coverage:  MBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))